Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Hatim M Jaber, Saja Ebdah, Sameer A Al Haj Mahmoud, Luay Abu-Qatouseh, Yazan H Jaber
Various COVID-19 vaccines can affect the immune system. Discrepancies have been noted in immune system characteristics, such as T-lymphocyte levels, between vaccinated and non-vaccinated individuals. This study investigates the variations in immune responses among the four administered COVID-19 vaccines, influencing factors, and clinical outcomes in Jordan. A total of 350 adults, who were at least two doses vaccinated, were interviewed and blood samples were collected for subsequent laboratory analyses. The study involved the quantification of T-cells specifically targeting anti-SARS CoV-2 using Flow cytometry analysis...
December 31, 2024: Human Vaccines & Immunotherapeutics
#22
JOURNAL ARTICLE
Feng Jiang, Xingui Ye, Ying Wang, Ning Tang, Jun Feng, Yuanxue Gao, Meiling Bao
The rise in pertussis incidence among infants in Guizhou, China underscores the need for maternal acellular pertussis vaccine (aP) immunization, a key strategy in protecting infants from severe health consequences. However, the willingness of pregnant women in Guizhou to receive this vaccine is not well-understood. This study aimed to explore pregnant women's intentions toward maternal pertussis vaccination in Guizhou and identify the associated factors. A questionnaire based on the health belief model, was administered in an exploratory cross-sectional study from January to February 2022...
December 31, 2024: Human Vaccines & Immunotherapeutics
#23
JOURNAL ARTICLE
Belayneh Shetie Workneh, Enyew Getaneh Mekonen, Alebachew Ferede Zegeye, Almaz Tefera Gonete, Tewodros Getaneh Alemu, Tadesse Tarik Tamir, Berhan Tekeba, Mulugeta Wassie, Alemneh Tadesse Kassie, Mohammed Seid Ali
Rotavirus is the most common cause of diarrhea in children worldwide. In 2016, rotavirus infection resulted in 258 173 300 episodes of diarrhea and 128 500 child deaths in the globe. The study aimed to assess the magnitude of Rotavirus vaccine dose-two dropout and associated factors among children who received rotavirus vaccine dose-one in sub-Saharan African countries. The appended and most recent demographic and health survey (DHS) dataset of 17 sub-Saharan African countries was used for data analysis. A total of 73,396 weighted samples were used...
December 31, 2024: Human Vaccines & Immunotherapeutics
#24
REVIEW
Chao Zhao, Yun Zhao, Jingran Li, Mingzhu Li, Yujing Shi, Lihui Wei
Current estimates of the HPV infection rate in China vary by geographic region (9.6-23.6%), with two age peaks in prevalence in women ≤20-25 years of age and 50-60 years of age. HPV-16, 52 and 58 are the most commonly-detected HPV genotypes in the Chinese population. In China, five HPV vaccines are licensed and several others are undergoing clinical trials. Multiple RCTs have shown the efficacy and safety of the bvHPV (Cervarix), Escherichia coli -produced bvHPV (Cecolin), Pichia pastoris -produced bvHPV (Walrinvax), qvHPV (Gardasil) and 9vHPV (Gardasil-9) vaccines in Chinese populations, including two studies showing long-term efficacy (≥8 years) for the bvHPV and qvHPV vaccines...
December 31, 2024: Human Vaccines & Immunotherapeutics
#25
JOURNAL ARTICLE
Bradley K Ackerson, Katia J Bruxvoort, Lei Qian, Lina S Sy, Sijia Qiu, Julia E Tubert, Gina S Lee, Jennifer H Ku, Ana Florea, Yi Luo, Radha Bathala, Julie Stern, Soon K Choi, Harpreet S Takhar, Michael Aragones, Morgan A Marks, Evan J Anderson, Cindy Ke Zhou, Tianyu Sun, Carla A Talarico, Hung Fu Tseng
Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against circulating sublineages is important to inform the potential need for vaccination with updated vaccines. In this test-negative study at Kaiser Permanente Southern California, sequencing-confirmed BA.4/BA.5- or XBB-related SARS-CoV-2-positive cases (September 1, 2022 to June 30, 2023), were matched 1:3 to SARS-CoV-2-negative controls...
December 31, 2024: Human Vaccines & Immunotherapeutics
#26
JOURNAL ARTICLE
Matilde Zornoza Moreno, Jaime Pérez-Martín, Marta Robles Mañueco
During the 2022-2023 season, the Region of Murcia (an autonomous community of Spain) introduced the influenza vaccination campaign in children aged 24-59 months with the live-attenuated influenza nasal spray vaccine. To expand coverage, a pilot study was conducted to include the 3- to 4-year population in 24 public schools. The aim of the study was to assess the experiences of parents and teachers involved in the project. This was a psychosocial qualitative study in which information was collected from a cohort of 23 parents and 17 teachers who attended three and two focus group sessions, respectively...
December 31, 2024: Human Vaccines & Immunotherapeutics
#27
JOURNAL ARTICLE
Laura Téblick, Marijana Lipovac, Freya Molenberghs, Peter Delputte, Winnok H De Vos, Alex Vorsters
Human papillomavirus (HPV) vaccines, primarily relying on neutralizing antibodies, have proven highly effective. Recently, HPV-specific antibodies have been detected in the female genital tract secretions captured by first-void urine (FVU), offering a minimally invasive diagnostic approach. In this study, we investigated whether HPV16-specific antibodies present in FVU samples retain their neutralizing capacity by using pseudovirion-based neutralization assays. Paired FVU and serum samples (vaccinated n = 25, unvaccinated n = 25, aged 18-25) were analyzed using two orthogonal pseudovirion-based neutralization assays, one using fluorescence microscopy and the other using luminescence-based spectrophotometry...
December 31, 2024: Human Vaccines & Immunotherapeutics
#28
JOURNAL ARTICLE
Mustafa Akkoyunlu
Like the other invasive encapsulated bacteria, Streptococcus pneumoniae is also covered with a polysaccharide structure. Infants and elderly are most vulnerable to the invasive and noninvasive diseases caused by S. pneumoniae . Although antibodies against polysaccharide capsule are efficient in eliminating S. pneumoniae , the T cell independent nature of the immune response against polysaccharide vaccines renders them weakly antigenic. The introduction of protein conjugated capsular polysaccharide vaccines helped overcome the weak immunogenicity of pneumococcal polysaccharides and decreased the incidence of pneumococcal diseases, especially in pediatric population...
December 31, 2024: Human Vaccines & Immunotherapeutics
#29
JOURNAL ARTICLE
Pan Liu, Xiaohan Yang, Hongyu Zhao, Lihua Liang, Minchai Chen, Aihua Yin
The epidemiological and clinical aspects of Human Papillomavirus (HPV) infection in women have been extensively studied. However, there is a lack of information regarding HPV characteristics in males. In this study, we conducted a retrospective and observational study of 3737 consecutive male individuals attending outpatient clinics of Guangdong Women and Children Hospital from 2012 to 2023 in Guangzhou, South China, to determine the age- and genotype-specific prevalence of HPV in men. The results showed the overall prevalence of HPV among men was 42...
December 31, 2024: Human Vaccines & Immunotherapeutics
#30
REVIEW
Paolo Bonanni, Stefano Castagna, Giovanni Gabutti, Sandro Giuffrida, Federico Marchetti, Rocco Russo, Rosa Prato, Francesco Vitale
Vaccine co-administration is a useful strategy for improving vaccine coverage and adherence. In Italy, an update to the national immunization program (NIP) in 2023 included recommendations for co-administration of pediatric vaccines, including the four-component vaccine for meningococcus B (4CMenB), pneumococcal conjugate vaccine (PCV), hexavalent vaccines, and oral rotavirus vaccines. Safety is a major concern when considering vaccine co-administration; therefore, a literature review of the available evidence on 4CMenB co-administration with PCV, hexavalent/pentavalent, and rotavirus vaccines was performed...
December 31, 2024: Human Vaccines & Immunotherapeutics
#31
JOURNAL ARTICLE
Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Marieke Heisen, Jessica Weaver, Kristen A Feemster, Bianca Chun, Thomas W Weiss, Jordana K Schmier
As higher-valent pneumococcal conjugate vaccines (PCVs) become available for pediatric populations in the US, it is important to understand healthcare provider (HCP) preferences for and acceptability of PCVs. US HCPs (pediatricians, family medicine physicians and advanced practitioners) completed an online, cross-sectional survey between March and April 2023. HCPs were eligible if they recommended or prescribed vaccines to children age <24 months, spent ≥25% of their time in direct patient care, and had ≥2 y of experience in their profession...
December 31, 2024: Human Vaccines & Immunotherapeutics
#32
REVIEW
Peter Kardos, Jaime Correia de Sousa, Ulrich Heininger, Andreas Konstantopoulos, C Raina MacIntyre, Donald Middleton, Terry Nolan, Alberto Papi, Adrian Rendon, Albert Rizzo, Kim Sampson, Alessandro Sette, Elizabeth Sobczyk, Tina Tan, Catherine Weil-Olivier, Birgit Weinberger, Tom Wilkinson, Carl Heinz Wirsing von König
Pertussis has several notable consequences, causing economic burden, increased strain on healthcare facilities, and reductions in quality of life. Recent years have seen a trend toward an increase in pertussis cases affecting older children and adults. To boost immunity, and protect vulnerable populations, an enduring approach to vaccination has been proposed, but gaps remain in the evidence surrounding adult vaccination that are needed to inform such a policy. Gaps include: the true incidence of pertussis and its complications in adults; regional variations in disease recognition and reporting; and incidence of severe disease, hospitalizations, and deaths in older adults...
December 31, 2024: Human Vaccines & Immunotherapeutics
#33
REVIEW
Michael Grant, Lian Ni Lee, Senthil Chinnakannan, Orion Tong, Jonathan Kwok, Nicole Cianci, Luke Tillman, Abhishek Saha, Vinnycius Pereira Almeida, Carol Leung
Cancer is a global health challenge, with changing demographics and lifestyle factors producing an increasing burden worldwide. Screening advancements are enabling earlier diagnoses, but current cancer immunotherapies only induce remission in a small proportion of patients and come at a high cost. Cancer vaccines may offer a solution to these challenges, but they have been mired by poor results in past decades. Greater understanding of tumor biology, coupled with the success of vaccine technologies during the COVID-19 pandemic, has reinvigorated cancer vaccine development...
December 31, 2024: Human Vaccines & Immunotherapeutics
#34
JOURNAL ARTICLE
Pierre-André Jarrot, Adrien Mirouse, Sébastien Ottaviani, Simon Cadiou, Jean-Hugues Salmon, Eric Liozon, Simon Parreau, Martin Michaud, Benjamin Terrier, Pierre-Edouard Gavand, Ludovic Trefond, Virginie Lavoiepierre, Jeremy Keraen, Daniel Rekassa, Bastien Bouldoires, Thierry Weitten, Damien Roche, Antoine Poulet, Caroline Charpin, Vincent Grobost, Marion Hermet, Magali Pallure, Chloe Wackenheim, Ludovic Karkowski, Pierre Grumet, Thomas Rogier, Nabil Belkefi, Vincent Pestre, Emilie Broquet, Amélie Leurs, Sophie Gautier, Valérie Gras, Pierre Gilet, Jan Holubar, Nadia Sivova, Nicolas Schleinitz, Jean-Marc Durand, Brice Castel, Alexandre Petrier, Robin Arcani, Baptiste Gramont, Philippe Guilpain, Hubert Lepidi, Pierre-Jean Weiller, Joelle Micallef, David Saadoun, Gilles Kaplanski
We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26...
December 31, 2024: Human Vaccines & Immunotherapeutics
#35
JOURNAL ARTICLE
Fanli Qu, Guanwen Wang, Ping Wen, Xiaoyu Liu, Xiaohua Zeng
Breast cancer is the leading cause of cancer-related death among women globally. Immunotherapy has emerged as a major milestone in contemporary oncology. This study aims to conduct a bibliometric analysis in the field of immunotherapy for breast cancer, providing a comprehensive overview of the current research status, identifying trends and hotspots in research topics. We searched and retrieved data from the Web of Science Core Collection, and performed a bibliometric analysis of publications on immunotherapy for breast cancer from 2013 to 2022...
December 31, 2024: Human Vaccines & Immunotherapeutics
#36
JOURNAL ARTICLE
Victor Fernandez-Alonso, Ruth Gil-Prieto, Maria Amado-Anton-Pacheco, Valentín Hernández-Barrera, Ángel Gil-De-Miguel
In 2020, there were approximately 50,865 anal cancer cases and 36,068 penile cancer cases worldwide. HPV is considered the main causal agent for the development of anal cancer and one of the causal agents responsible for the development of penile cancer. The aim of this epidemiological, descriptive, retrospective study was to describe the burden of hospitalization associated with anal neoplasms in men and women and with penis neoplasms in men in Spain from 2016 to 2020. The National Hospital Data Surveillance System of the Ministry of Health, Conjunto Mínimo Básico de Datos, provided the discharge information used in this observational retrospective analysis...
December 31, 2024: Human Vaccines & Immunotherapeutics
#37
JOURNAL ARTICLE
Abdu A Adamu, Duduzile Ndwandwe, Rabiu I Jalo, Charles S Wiysonge
Despite the availability of effective vaccines for preventing common childhood infectious diseases, there is still significant disparities in access and utilization across many low- and middle-income countries (LMIC). The factors that drive these disparities are often multilevel, originating from individuals, health facilities, health systems and communities, and also multifaceted. Implementation science has emerged as a field to help address "know-do" gaps in health systems, and can play a significant role in strengthening immunization systems to understand and solve implementation barriers that limit access and uptake within their contexts...
December 31, 2024: Human Vaccines & Immunotherapeutics
#38
JOURNAL ARTICLE
Yutong Zhang, Jinzhao Cui, Fengfeng Liu, Yang Song, Quanyi Wang, Yanzhe Liu, Yanping Zhang, Zhongjie Li, Zhaorui Chang
The Enterovirus A71 (EV-A71) vaccine was introduced in China in December 2015 as a preventive measure against hand, foot, and mouth disease (HFMD) caused by EV-A71. However, the effectiveness of the vaccine (VE) in real-world settings needs to be evaluated. We conducted a test-negative case-control study to assess the effectiveness of EV-A71 vaccines in preventing EV-A71-associated HFMD. Children aged 6-71 months with HFMD were enrolled as participants. The case group comprised those who tested positive for EV-A71, while the control group comprised those who tested negative for EV-A71...
December 31, 2024: Human Vaccines & Immunotherapeutics
#39
JOURNAL ARTICLE
Ankur Tiwari, Karl Alcover, Elizabeth Carpenter, Katryna Thomas, Julia Krum, Alexander Nissen, Spencer Van Decar, Todd Smolinsky, Franklin Valdera, Timothy Vreeland, Markus Lacher, Giuseppe Del Priore, William Williams, Alexander Stojadinovic, George Peoples, Guy Clifton
Cell-based therapeutic cancer vaccines use autologous patient-derived tumor cells, allogeneic cancer cell lines or autologous antigen presenting cells to mimic the natural immune process and stimulate an adaptive immune response against tumor antigens. The primary objective of this study is to perform a systematic literature review with an embedded meta-analysis of all published Phase 2 and 3 clinical trials of cell-based cancer vaccines in human subjects. The secondary objective of this study is to review trials demonstrating biological activity of cell-based cancer vaccines that could uncover additional hypotheses, which could be used in the design of future studies...
December 31, 2024: Human Vaccines & Immunotherapeutics
#40
JOURNAL ARTICLE
Natalie L Rincon, Kelsey Rae McDowell, Darien Weatherspoon, Tiarney D Ritchwood, Daniel J Rocke, Eric Adjei Boakye, Nosayaba Osazuwa-Peters
In 2018, the Food and Drug Administration expanded the age of eligibility for the human papillomavirus (HPV) vaccine to 27 to 45 years. However, it is unclear if there are racial/ethnic disparities in HPV vaccine uptake for this age-group following this expanded recommendation. We aimed to identify any disparities in HPV vaccine in 27 to 45 year-olds based on sociodemographic factors. We analyzed nationally representative, cross-sectional data from the 2019 National Health Interview Survey ( n = 9440)...
December 31, 2024: Human Vaccines & Immunotherapeutics
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
